We have seen a lot of movement in regulatory approval of Covid-19 vaccines over the past two weeks,
as vaccination campaigns begin to roll out. When tracking the Covid-19 vaccine landscape, it is
important to keep in mind the difference between emergency use authorization and full authorization.
Most Covid-19 vaccine approvals received thus far have been limited to emergency use.
We are frequently asked why some data about vaccines purchased by Russia and China appear to be missing from our data. The answer is because both countries control largely state-owned vaccine development and manufacturing chains, and, in part because of this, are notably less transparent than some other countries about advance purchases for domestic use as well as exports.